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Summary
The immune response to Helicobacter pylori involves different mechanisms that are both
protective and damaging to the host. The innate and the adaptive immune responses lead
to inflammatory as well as anti-inflammatory responses, allowing for persistence of many
infections. Thus, developing new therapeutics and effective vaccines against H. pylori has
proven to be arduous. Despite many immunisation experiments, using various routes of
immunisation with classical as well as recombinant H. pylori vaccines (urease, CagA, HP-
-NAP, HspA, DNA, chimeric molecules, live vectors, microspheres), no effective vaccine is
currently available for humans. New directions for successful vaccine construction should
follow a profound knowledge of immunopathological events during natural H. pylori in-
fection and factors leading to resolution of infection: mandatory is a new knowledge about
the interplay of the innate response to H. pylori, mucosal inflammation, H. pylori virulence
factors inducing immune responses, regulation of the adaptive responses to H. pylori as
well as construction of novel vaccine platforms for achieving a broad immune response,
leading to a sterilizing immunity.
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tion
Introduction
Helicobacter pylori is well established as the causative
agent of chronic gastritis. Other diseases associated with
H. pylori infection include duodenal ulcer, gastric ulcer
and gastric carcinoma. An etiological role of this organ-
ism in the development of these diseases is still unclear,
although evidence strongly supports its major role. H.
pylori infects an estimated 50 % of the world’s popula-
tion, but only a small proportion of individuals develop
clinical symptoms of gastritis, peptic ulceration or gas-
tric cancer. The variations in disease presentation may
be due to factors that influence the bacterial virulence or
the host response to infection with H. pylori. The local
cellular and humoral immunity as well as non-specific
mucosal defence mechanisms have been suggested to be
involved in the pathogenesis of H. pylori-related diseases
as well (1).
Infection with Helicobacter pylori induces strong local
immune responses in the gastric mucosa of H. pylori-in-
fected hosts. It is characterized by the recruitment of neu-
trophils, T and B lymphocytes, plasma cells, macrophages
and dendritic cells (DCs), together with epithelial cell
damage. Gastric mucosa of H. pylori-infected individuals
contains increased concentrations of several pro-inflam-
matory cytokines such as interleukin (IL)-1b, IL-2, IL-6,
IL-8, IL-12 and tumour necrosis factor (TNF)-a and anti-
-inflammatory cytokines IL-4 and IL-10 (2). The increased
production of inflammatory cytokines in response to H.
pylori infection results in the development and recruit-
ment of specific T lymphocytes sensitized to H. pylori anti-
gens and B cells producing immunoglobulin (Ig)A and
IgG. Still, the immune response cannot eliminate the
bacteria, and unless antibiotic treatment is used, the in-
fection is usually lifelong (2,3).
When considering the immunity against such a suc-
cessful and adapted pathogen like H. pylori, we must
first reconsider some of the main protective forces of the
host that could damage the microorganism and prevent
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the infection. Since H. pylori colonises gastric mucosa,
the gastric protective mechanisms play a central role in
the parasitic-host events in H. pylori infections (1). The
human stomach, as part of gastrointestinal tract, is ex-
posed to a broad spectrum of dietary and bacterial anti-
gens. The stomach epithelium is the primary cellular
barrier between the outside world and the host. The im-
mune system must effectively protect the stomach against
pathogens without damaging the epithelium or perturb-
ing its functions. Furthermore, the immunity must dis-
tinguish microbial from dietary antigens to prevent an
immune response against dietary antigens (2,4).
Adaptation Mechanisms of H. pylori to the Host
During infection H. pylori colonises the surface of the
gastric epithelium especially in the antrum. H. pylori does
not reside within the acidic environment in the lumen of
the stomach. Instead, the microorganism colonises more
neutral microenvironment of the mucus layer lining and
the surfaces of the epithelial cells. In addition, the H. py-
lori produces an urease. An ammonia, produced by the
enzyme, forms a cloud around the bacterium, thus pro-
tecting it from the acid. Because the turnover of the gas-
tric mucus layer and gastric epithelial cells is very rapid,
H. pylori has developed several adaptations that avoid
its rapid removal from the stomach. The specialised mo-
tility of H. pylori allows it to move from the lumen down
through the mucus onto the gastric cell surface. H. pylori
developed a vast number of adhesion molecules, inter-
acting with various structures in the mucus and stomach
epithelial surfaces (5).
A special adaptation may be the feature that H. py-
lori expresses adhesion molecules only in certain phases
of bacterial growth. This means that bacteria are bound
to the gastric epithelium in certain growth phases and in
other phases they are not. This interchangeable binding
prevents H. pylori from being removed completely from
the stomach together with the superficial epithelial cells
that are shed into the lumen. In this way, attached and
unattached bacteria may exist in the stomach all the time.
While the attached bacteria are shed together with the
stomach epithelia, the unattached bacteria are able to in-
fect new yet uninfected epithelial lining. This is one of
the proposed mechanisms that enable H. pylori to persist
in the stomach (6).
Inflammatory Response of the Host
Microbial invasion is, in part, prevented by the epi-
thelial tight junctions and is complemented by mucus pro-
duction and various antibacterial proteins such as lyso-
zyme, lactoferrin, interferon and defensin/cryptidin. In
response to epithelial stress (chemical, microbial, toxic),
inflammatory changes are initiated by the release of cy-
tokines and other mediators, which recruit and activate
polymorphonuclear cells, monocytes and mast cells. The
host innate immune system plays a key role in the initi-
ation and the subsequent progression of the H. pylori-as-
sociated pathogenesis (7). Gastric epithelial cells (GECs)
are primary target for H. pylori infection, and actively
contribute to the innate immune responses by signalling
through pattern recognition receptors, such as Toll-like
receptors (TLRs). GECs are the first point of contact for
H. pylori and express TLRs that may activate an innate
immune response. Although lipopolysaccharide (LPS) is
the classical bacterial ligand for TLR4, H. pylori-derived
LPS has been reported to signal through TLR-2 and has
low binding affinity for the TLR4. H. pylori was shown
to inhibit macrophage release of nitric oxide in response
to H. pylori LPS in a mouse model of infection. H. pylori
LPS was also shown to suppress TLR-4 signalling, but
enhance IL-12 and IL-18 production, which was suggest-
ed to be linked to the chronic inflammation commonly
seen during infection (8).
Inflammation is a crucial player in the H. pylori im-
mune response. During inflammation resulting from the
infection, bone marrow-derived mesenchymal stem cells
are recruited to the gastric mucosa. These cells are thought
to be underlying promoters of gastric cancer. A recent
study shows that H. pylori infection of gastric epithelial
cells induces migration of mesenchymal stem cells, which
was dependent upon NF-kB activation and TNF-a pro-
duction in an in vitro model (9).
Specific Immune Responses
Apart from the non-specific inflammatory response,
the immune responses are relatively sparse in uninfected
stomachs. The intra-epithelial lymphocytes (IEL) are all
T cells and the majority have the suppressor/cytotoxic
(CD8) phenotype. The lamina propria contains both T
and B lymphocytes, and the majority of the T cells are of
helper (CD4) phenotype. The plasma cells in the lamina
propria secrete predominantly IgA. IgA is selectively
transported across the epithelial surfaces by the poly-
meric immunoglobulin receptor (secretory component)
and can provide immunity without inducing much in-
flammation (10).
D’Elios et al. (11) found high mRNA expression of
interferon (IFN)-g, TNF-a, and IL-12, but not IL-4 in
antral biopsies from the H. pylori-infected patients, but
not from uninfected controls. Furthermore, upon in vitro
lysate stimulation, T lymphocytes from the H. pylori-in-
fected patients derived CD4+ T cell clones mostly (over
80 %) producing IFN-g, but not IL-4 or IL-5. Results pro-
vide evidence for H. pylori-specific Th1 effectors in the
gastric antrum of H. pylori-infected patients.
Besides Th1 response, H. pylori is able to drive gas-
tric Th17 response. Amedei et al. (12) demonstrated that
in vitro produced T cells from H. pylori-infected patients
with distal gastric adenocarcinoma produced IL-17 and
IL-21 in response to the secreted peptidyl prolyl cis-trans-
-isomerase of H. pylori.
Innate immune sensing and signalling is the starting
point of specific immunity. Central to this process, den-
dritic cells (DCs) integrate innate information and con-
vey it to the lymphocytes. The DCs activation by H. py-
lori is mediated largely by the TLRs (13).
H. pylori has developed a variety of mechanisms to
persist in the gastric mucosa. Regulatory T cells (Tregs)
are induced during infection. They express the FoxP3
transcription factor and inhibit inflammatory T cell re-
sponses by secretion of inhibitory cytokines IL-10 and
TGF-b. Tregs are induced when TGF-b is present, along
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with PDL-1 expression on antigen-presenting cells (13,
14). A unique feature of the gastric epithelium is the abil-
ity to act as antigen-presenting cells in expressing class
II MHC and co-stimulatory and co-inhibitory molecules.
Gastric epithelial cells were shown to produce TGF-b af-
ter exposure to H. pylori (12). H. pylori-induced TGF-b
was shown to inhibit CD4+ T cell proliferation and lead
to Treg development, suggesting a mechanism that it uses
to subvert the host response and persist in the gastric
mucosa (15).
H. pylori Virulence Factors and Immune
Responses
In the past decade extensive studies confirmed the
pathogenic role of the cytotoxin-associated gene-patho-
genicity island (cagPAI) as a virulence factor linked to
carcinogenesis. Recently, CagA has been termed an on-
coprotein due to its intracellular activities that lead to
dysregulation of cell division (16,17). Once inside cells,
CagA is phosphorylated by Src tyrosine kinases. CagA
increases the motility of gastric epithelial cells (18), hence
its potential for a metastatic role. CagA also induces over-
expression of microRNAs, leading to increased NF-kB and
Erk1/2 signalling, targeting, and inducing epithelial-me-
senchymal transition and intestinal metaplasia of gastric
epithelial cells (19).
The vacuolating cytotoxin A (VacA) virulence factor
has long been associated with host damage by forming
pores in host cell membranes, disrupting membrane traf-
ficking and inducing apoptosis. Mechanisms associated
with apoptosis include VacA-induced inhibition of Stat3
and Bcl-2 cell survival proteins (20). In addition, a cas-
pase-independent process is activated, which involves
the histone-binding high mobility group box 1 protein,
consistent with known necrosis pathways. The end re-
sult is epithelial cell necrosis and release of inflamma-
tory proteins that contribute to pathogenesis (20).
H. pylori cell division-related gene A (cdrA) was
shown to induce NF-kB activation and IL-8 production.
This expression of cdrA is accompanied by higher levels
of mucosal IL-8 in the cdrA-positive samples compared
to the cdrA-negative samples (21).
Urease enables H. pylori to colonise the acidic envi-
ronment of the stomach. A protective mechanism of the
host, CD46, C3b/C4b-binding complement regulator
bound to H. pylori, inhibits urease and thus enables the
bacteria to survive in an acidic environment (22). The
urease B subunit leads to Th17 responses in the mouse
model of H. pylori infection (23). When recombinant
urease B was incubated directly with mouse splenic
lymphocytes, the number of IL-17-producing cells in-
creased and when macrophages were incubated with re-
combinant urease B, IL-6 and IL-23 were produced to
support Th17 development.
H. pylori lipopolysaccharide (LPS) has been shown
to induce weaker immune responses than LPS from
other bacteria. Particularly, LPS from H. pylori did not
induce strong IL-1b, IL-6, or IL-8 responses (24), as other
bacterial LPSs do. H. pylori LPS was also shown to in-
duce little NF-kB activation through TLR4, but was shown
to induce IL-12 and IL-18 responses, which are thought
to be pro-inflammatory.
Progress in Vaccine Development against
H. pylori
Numerous studies of possible vaccines against H.
pylori demonstrate that it is possible to achieve an im-
mune response that is effective enough for its therapeu-
tic eradication (2). Efforts to develop a vaccine for the
prevention and treatment of H. pylori infection began in
earnest in the early 1990s, with the recognition that H.
pylori is the most important cause of peptic ulcer disease
and gastric cancer. Although the prevalence of H. pylori
is declining in developed countries, the current under-
standing is that vaccination of infants to prevent H. py-
lori infection would be cost effective. However, one can
hardly escape the impression that results to date have
been disappointing. Sterilizing immunity has rarely been
achieved in animal models, there is no consensus on the
choice of antigens, adjuvants, or delivery route, and the
few clinical trials have generally been unsuccessful. Ne-
vertheless, some progress is being made in the identifi-
cation of novel antigens and in our understanding of
mechanisms of protection, which increasingly focuses on
the role of Th1- and Th17-biased cellular immune re-
sponses, as well as Tregs (25).
The study by Borody et al. (26) tested the hypothesis
that an impaired immune response may contribute to
failed eradication after standard antibiotic therapy. The
ability of lymphocytes to produce IFN-g and IL-4 was
measured. They found a significant reduction in the se-
cretion of IL-4 from blood T cells in subjects failing to
eradicate H. pylori, compared with those who success-
fully eradicated the infection in lymphocyte cultures. A
significant difference in IL-4 secretion was also detected
in antigen-stimulated cultures, compared with that in H.
pylori-positive subjects. Low levels of IL-4 secretion were
detected irrespective of the number of courses of antibi-
otic therapy. In our experiments, we did not find differ-
ences in cytokine production in non-stimulated lympho-
cyte cultures.
Moss et al. (27) developed a vaccine platform using
a computational method to predict novel T cell epitopes.
The multi-epitope vaccine was administered intranasally
or intramuscularly to H. pylori-infected mice, followed
by a boost with the peptides formulated in liposomes
with CpG oligonucleotides and heat-labile enterotoxin.
The vaccine induced a broad immune response, which
was determined by IFN-g production, and led to a steril-
izing immunity 32 weeks after challenge in five out of
19 mice.
Another promising vector platform for expression of
H. pylori antigens was developed by Iankov et al. (28).
They produced a measles virus (MV) vaccine strain en-
coding the H. pylori neutrophil-activating protein (NAP).
Nine months post vaccination all animals immunized
with MV strains, which expressed the secretory NAP an-
tigen, developed a strong humoral immunity against
NAP. IFN-g ELISpot assay confirmed the effective NAP-
-specific cell-mediated immunity. Their experiments de-
monstrated that immunization with a live replication-
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-competent vaccine expressing H. pylori molecules (NAP
or potentially CagA, VacA, etc.) induced not only robust
antibody production but also distinctive cell-mediated
response against H. pylori antigens.
Improved efficacy of vaccines may be achieved with
new vaccine formulations that include multiple antigens
and use different methods to optimize cellular immuni-
ty. Chen et al. (29) used a H. pylori oipA gene-encoded
construct co-delivered by IL-2 and B subunit heat-labile
toxin of Escherichia coli gene-encoded construct. Intra-
dermal co-delivery of adjuvant(s) enabled the shift of
the immune response from being Th2- to being Th1-bi-
ased, which resulted in a greater reduction in bacterial
load after H. pylori infection. A similar approach used
Salmonella vector construct that expressed fusion pro-
teins complexed with H. pylori CagA, VacA and UreB in
different arrangements (30). Oral therapeutic immuniza-
tion significantly decreased H. pylori colonization in the
stomach; protection was related to the combination of
Th1, serum IgG and mucosal IgA responses.
In our attempt to construct effective vaccine formu-
lation, we constructed a chimeric flagellin, in which both
terminal segments of H. pylori flagellin (that is TLR5-non-
-activating flagellin) were replaced by the corresponding
segments from TLR5-activating E. coli flagellin (25). Re-
combinant chimeric flagellin folded correctly and was able
to activate TLR5. Significantly increased serum IgG and
IgA antibody responses were determined in mice vacci-
nated with chimeric flagellin in comparison with mice
vaccinated with a control protein (FlaA) or negative con-
trol. Antibody titers remained high even 8 months after
the last immunization. Antibodies were able to bind na-
tive flagellin from H. pylori lysate. Vaccination with chi-
meric flagellin provided mice with significant protection
against H. pylori. The approach of chimeric flagellin can
therefore generate effective immunogens that enable ac-
tivation of innate and adaptive immune response and can
be used to construct efficient vaccines against H. pylori
or other flagellated bacteria that evade TLR5 recognition.
Guo et al. (30) used a fusion protein construct of chol-
era toxin B subunit expressed in E. coli and a UreA epi-
tope of H. pylori urease to develop a vaccine with good
immunogenicity and immunoreactivity that could induce
specific neutralizing antibodies. However, the efficiency
of the vaccine should still be confirmed by a sterilizing
immunity trial, since urease vaccine targets have a long
history of rather disappointing results.
Our Experiences – Mucosal Immunity in
H. pylori Infection
The local cellular and humoral immunity in gastric
mucosa was suggested to be involved in the pathoge-
nesis of H. pylori-related diseases as well. It is well docu-
mented that a simple chronic gastritis is associated with
an excessive local IgG production, T cell infiltration and
increased epithelial HLA class II expression (1,31).
In our studies, we defined changes in the local im-
mune response between the chronic gastritis, associated
with H. pylori (urease-positive gastritis) and the chronic
urease-negative gastritis. In order to define the type of
local immune response that may predict the outcome of
H. pylori infection, we analysed lymphocytes infiltrating
inflamed gastric mucosa. After isolation of gastric mu-
cosa lymphocytes, we evaluated the expression of lym-
phocyte molecules that determine differences in lympho-
cyte activation between the gastritis caused by H. pylori
and other types of gastritis (32).
We demonstrated a significant increase in IL-2 recep-
tor expression in gastric mucosa T cells in ulcer patients
compared with non-ulcer dyspeptic patients (33). In the
following study we analysed the expression of IL-2 re-
ceptor and intracellular lymphokine (IFN-g, IL-4) pro-
duction in gastric mucosa infiltrating T lymphocytes in
duodenal ulcer patients before and after H. pylori eradi-
cation. We detected a prevalence of Th1 T cells compared
to Th2 T cells in gastric mucosal tissue. A proportion of
Th2 T cells did not change significantly in patients one
or twelve months after H. pylori eradication. On the other
hand, the percentage of IFN-g-producing cells diminished
significantly after H. pylori eradication (34).
Our results suggest that long-term lymphocyte gas-
tric mucosa infiltration after H. pylori eradication may
reflect homing of memory lymphocytes induced by mu-
cosal antigen-presenting cells. Dendritic cells (DCs) and
other antigen-presenting cells constitute the initial im-
mune response towards H. pylori. Immature DCs in the
mucosa-associated lymphoid tissue are capable of mi-
grating through epithelial tight junctions to gain access
to the gastrointestinal lumen (35). Upon exposure to bac-
terial components, immature DCs differentiate into ma-
ture, antigen-presenting cells with upregulated expres-
sion of major histocompatibility complex (MHC) class I
and II, adhesion/costimulatory molecules and induce
production of inflammatory cytokines (36).
As DCs play a pivotal role in shaping the immune
response, we investigated whether the strain-dependent
differences in H. pylori-derived LPS influence the activa-
tion of the DCs and cytokine secretion. To examine the
modulatory role of H. pylori strains in antigen presenta-
tion, we use cathepsin X inhibitor, a monoclonal anti-
body 2F12. Cathepsin X activity promotes adhesion of
DCs as well as their phagocytic function (37). We dem-
onstrated that cathepsin X mediates the activation of b2
integrin receptor Mac-1 (CD11b/CD18), and that it may
also regulate the maturation of DCs, a process which is
crucial for the initiation of adaptive immunity (38).
We also examined dendritic cells stimulated by H.
pylori isolated from patients with repeated antibiotic era-
dication failure and found that in them human leuko-
cyte antigen (HLA-DR), CD86, TLR-2, and interleukin-8
(IL-8) were less expressed compared to H. pylori strains
susceptible to antibiotic therapy; the latter expressed
lower production of IL-10 (39). Polymyxin B inhibition
of LPS reduces IL-8 secretion in the group of H. pylori
strains susceptible to antibiotic therapy. The differences
in IL-8 secretion between both groups are LPS depend-
ent, while the differences in secretion of IL-10 remain un-
changed after LPS inhibition. Inhibitor of cathepsin X Mab
2F12 reduced the secretion of IL-6, and the secretion was
significantly lower in the group of H. pylori strains iso-
lated from patients with repeated antibiotic eradication
failure. Our results suggest that different H. pylori strains,
susceptible/resistant to antibiotic eradication therapy,
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differ in their LPS capability to induce DC maturation
and antigen-presenting function.
Conclusions
The immune response to Helicobacter pylori involves
innate and adaptive immune changes, which lead to
damaging inflammatory reactions, but may also allow
persistence of infection. Despite many immunisation ex-
periments, using various routes of immunisation with
classically as well as recombinantly prepared H. pylori
vaccines (urease, CagA, HP-NAP, HspA, DNA, chimeric
molecules, live vectors, microspheres), no effective vac-
cine is currently available for humans. New directions
for successful vaccine construction should follow a pro-
found knowledge of immunopathological events during
natural H. pylori infection and factors leading to resolu-
tion of infection: mandatory is the new knowledge about
the interplay of the innate response to H. pylori, mucosal
inflammation, H. pylori virulence factors inducing im-
mune responses, regulation of the adaptive responses to
H. pylori as well as construction of novel vaccine plat-
forms for achieving a broad immune response, leading
to sterilizing immunity.
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